In8bio Inc

$3.58
(as of Jun 6, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for In8bio Inc

Stock Price
$3.58
Ticker Symbol
INAB
Exchange
NASDAQ

Industry Information for In8bio Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for In8bio Inc

Website
https://in8bio.com
Country
USA
Full Time Employees
18

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

Fundamentals for In8bio Inc

Market Capitalization
$13,125,623
EBITDA
$-24,726,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.44
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
90,771,904
Percent Owned by Insiders
4.89%
Percent Owned by Institutions
23.88%
52-Week High
52-Week Low

Technical Indicators for In8bio Inc

50-Day Moving Average
200-Day Moving Average
RSI
33.7
ATR
0.02

Analyst Ratings for In8bio Inc

Strong Buy
2
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About In8bio Inc

Jun 2, 2025, 7:30 AM EST
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. See more.
Mar 18, 2025, 8:05 AM EST
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. See more.
Mar 13, 2025, 4:05 PM EST
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseasesContinued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact programs forwardMaintaining cash position to support operations and achievement of anticipated development milestones throughout 2025 and into 2026 See more.
Mar 3, 2025, 9:28 AM EST
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletionUnlike traditional TCEs and CAR-T therapies, γδ T cells naturally secrete lower levels of IL-6, potentially reducing the risk of cytokine release syndrome (CRS) and neurotoxicity (ICANs)Access the webcast discussing the novel γδ TCE platform today at 10:30 a.m. See more.